Reading VYNE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VYNE free→Reading VYNE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VYNE free→QuarterlyIQ Insights · VYNE
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed in a Current Report on Form 8-K filed by VYNE Therapeutics Inc. (the “Company”) on September 12, 2025, the Company received a notification from The Nasdaq Stock Market, LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing b…
shall have the meanings ascribed to such terms in the Merger Agreement. The Amendment provides that VYNE may provide certain pre-funded warrants (the “Pre-Funded Warrants”), substantially in the form attached to the Amendment as Exhibit E thereto, to holders of Yarrow capital stock in the event that they would receive, pursuant to the Exchange Ratio, a number of shares of the common stock, $0.0001 par value per share, of VYNE (“VYNE Common Stock”), that (when aggregated with all Securities th…
Entry into a Material Definitive Agreement. Merger Agreement On December 17, 2025, VYNE Therapeutics Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Yarrow Bioscience, Inc., a Delaware corporation (“Yarrow”), and Yellow Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), pursuant to which, among other matters, and subject to the satisfaction or waiver of…
Regulation FD Disclosure. On December 17, 2025, the Company and Yarrow issued a joint press release announcing the entry into the Merger Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in the press release is not incorporated herein by reference. The Company and Yarrow plan to hold a joint conference call on December 17, 2025 at 8:30 AM Eastern Ti…
Changes in Control of Registrant. To the extent required by this Item, the information included in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. To the extent required by this Item, the information included in
Unregistered Sales of Equity Securities. To the extent required by this Item, the information included in
of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 11, 2025, VYNE Therapeutics Inc. (the “Company”) received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common stock (the “Common Stock”) was below $1.00 per…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Directors On August 11, 2025, Christine Borowski, Ph.D. provided notice to the board of directors (the “Board”) of her resignation as member of the Board and as a member of the Nominating and Corporate Governance Committee effective immediately. On August 13, 2025, Anthony Bruno provided notice to the Board of his resignation as memb…
of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Results of Operations and Financial Condition. The information set forth below in the second paragraph of
of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.